Twist Bioscience Corporation announced on September 2, 2025, a collaboration with Synthetic Design Lab (SDL), a next-generation therapeutics company. This partnership aims to leverage Twist's synthetic biology platform to support SDL's efforts in developing advanced therapeutic solutions.
The collaboration highlights Twist's role in enabling innovative research and development in the therapeutics space. By working with SDL, Twist expands its engagement in cutting-edge biological engineering applications.
This strategic alliance underscores Twist's commitment to advancing science through its unique DNA synthesis platform, contributing to the development of new treatments and therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.